Entrada Therapeutics Overview
Latest PEG ratio for Entrada Therapeutics: 196.71 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow196.71
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
The latest PEG ratio for TRDA is 196.71. That is above the sector sector average of 4.02. Investors often review this figure alongside Entrada Therapeutics's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, TRDA currently prints 196.71 for PEG ratio, while the sector average sits near 4.02. That is roughly 4791.4% above the sector mean. Large gaps often invite a closer look at Entrada Therapeutics's growth, margins, and balance sheet.
A PEG ratio of 196.71 for Entrada Therapeutics is not 'good' or 'bad' on its own. Compare it with the peer average (4.02) and with TRDA's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting TRDA's PEG ratio (196.71), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
